Letters by company

Mattel INC

3 letters discussing MAT. Everything written about it on this site is on its ticker page.

Southeastern Asset Management 2Q26 Commentary Longleaf Partners Fund argues that speculative AI-linked market leaders have become detached from cash-flow fundamentals while its lower-multiple holdings offer greater upside with less risk. The fund engaged with Mattel and supported changes at Fortune Brands, while adding a new healthcare position, exiting Bio-Rad, and selling spun-off FedEx Freight above appraisal. 2Q26 +3.9% ACI $6.1BAVTR $9.4BCNX $5.4BFBIN $5.4B
Patient Capital Management 1Q26 Portfolio Activity & Attribution Patient Opportunity Equity Strategy added Adobe after the software selloff and replaced FBTC with IBIT to retain Bitcoin exposure, while selling Alibaba at estimated intrinsic value and exiting Mattel and Peloton to fund new ideas. The strategy argues that concentrated energy exposure offers an anti-fragile diversifier, with offshore drilling and pipeline constraints supporting Noble, Seadrill and Energy Transfer. 1Q26 -6.0% ADBE $110BCHYM $12BET $73BIBIT $173B
Patient Capital Management 3Q25 Portfolio Recap Patient Opportunity Equity Strategy converted and trimmed Precigen after Papzimeos won early FDA approval, while retaining conviction in its commercial opportunity and pipeline. The strategy added aggressively to UnitedHealth during its sell-off and increased selected laggards including Crocs, Mattel, IAC and Biogen while keeping exposure to momentum areas. 3Q25 +14.1% PGEN $2.6BUNH $350BBIIB $33BCROX $5.9B